We are thrilled to congratulate the WAINUA team from AstraZeneca on being selected as an ELITE100 Marketing Team! Don’t miss a chance to meet them and all of our other incredible ELITE winners tomorrow on June 18th at 230 FIFTH Rooftop in NYC for our celebration of the pharma industry’s best and brightest: https://lnkd.in/g4nE39eW
PM360 Magazine’s Post
More Relevant Posts
-
Listen to Mohammed Ali of Astellas Pharma on why he is coming back to #DPHARM for the 9th year in a row! "It is a great opportunity to understand what is happening across each other's organizations, where the opportunities and challenges are, and potentially to find solutions together." Learn more about DPHARM: DPHARMconference.com #DPHARM2024 #clinicalinnovation #clinicalresearch #clinicaltrials
To view or add a comment, sign in
-
Future Pharma 2024 is around the corner! Adam Alfi and Mai Shafei are attending the World’s Leading Pharma Commercialization Event. Stay tuned for more insights from the event! #futurepharma2024
To view or add a comment, sign in
-
On both sides of the Atlantic pharma companies are presenting cases to the courts and to national regulators that the innovation cash pipelines will be disrupted, forcing them to either cut back and delay launches or move operations to Asia Pacific or Latin America. Find out more in our newly published whitepaper featuring industry experts: · Christoph Glaetzer, Dipl.Kfm., Chief Global Value and Access at Johnson & Johnson Innovative Medicine · Ricardo Werner Marek, President Europe & Canada at Takeda · Andy Powrie-Smith, Executive Director, Communications & Partnerships at EFPIA - European Federation of Pharmaceutical Industries and Associations Access the full whitepaper here: https://bit.ly/3Vh46Y2
To view or add a comment, sign in
-
Two weeks ago, over 60 of us came together in NYC for a fantastic day of discussion at the Bioethics International Roundtable as leaders from across the biopharmaceutical industry. As always, the event was inspiring as we explored key topics such as clinical trial diversity, patient centricity, access to medicines globally, and the rapidly evolving focus on ESG in our industry. I was particularly inspired by the discussion focused on sharing individual results to clinical trial participants, a topic that has been a passion for me since my GSK days where I was deeply involved in the development of plain language summaries, internally and externally, as it was a new component of clinical trial transparency spurred on by the EU Clinical Trial Regulation requirement. From that point, it simply made sense to move from sharing aggregate results to sharing individual results. So proud to represent Legacy Health Strategies in this forum and to have developed the capability to operationalize sharing of individual and aggregate results via a digital communication platform connecting sponsors and participants, before, during and after clinical trials. Looking forward to collaborating further to ensure the industry lives up to its full potential for good! - CEO Jessica Scott, MD, JD #BioethicsInternational #BEI #HealthEquity #ClinicalTrials #PatientEngagement #ESG #Transparency #LegacyHealthStrategies #DrugDevelopment #RoundTable #Pharma #NYC
To view or add a comment, sign in
-
BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree This week, several Big Pharma companies reported first-quarter 2024 financial results. Biogen beat Wall Street’s profit expectations and reported a spike in the uptake of its Alzheimer’s disease therapy Leqembi, and Novartis raised its 2024 outlook on strong drug sales. Meanwhile Roche’s Q1 sales slipped due to a continued drop in demand for COVID-19 products and the appreciation of the Swiss franc. However, the biggest news of the week was Bristol Myers Squibb’s announcement that it will reduce its headcount by 6%, laying off approximately 2,200 employees, or nearly 30% of all biopharma jobs lost so far in 2024, according to BioWorld. https://lnkd.in/eh8B-JDg
To view or add a comment, sign in
-
💊𝗕𝗹𝗼𝗴𝗴𝗲𝗿 #ConnectingInforming #DrugDiscoverytoDrugDelivery 💻𝗩𝗶𝗱𝗲𝗼 𝗖𝗼𝗻𝘁𝗲𝗻𝘁 𝗖𝗿𝗲𝗮𝘁𝗼𝗿 YouTube: RSK Life Science Media 📈𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝘁-LinkedIn/Marketing/Media/Events, Brand Champion
#News: AstraZeneca on Monday morning unveiled its ambitious plan to be one of the fastest growing pharma companies by the end of the decade. In what CEO @Pascal Soriot described as “a new era of growth,” the UK #pharma said it is targeting $80 billion in total revenue by 2023, which is 75% higher than what it raked in last year at $45.8 billion, according to a Monday press release ahead of its Investor Day in Cambridge, UK. While many of AstraZeneca’s pharma peers have set high expectations for certain top products or near-term sales growth, the British drugmaker’s new declaration is bold in both scope and timeline. To reach its goal, AstraZeneca would have to grow by more than 8% every year over seven years — compared to a 5%-7% target separately set by GSK and Johnson & Johnson (which would similarly put it at $80 billion by 2030), or a 5% target set by Novartis. With pandemic-era exceptions, very few drugmakers have managed to bring in $80 billion in pharma sales alone. Read more from.Endpoints News 👇🏽 https://lnkd.in/eBxZAwBn
To view or add a comment, sign in
-
On the cross-country flight home from a wonderful and busy BIO International Convention, I spent some time reflecting on three years here at the National Pharmaceutical Council. I still remember flying to DC as the brand-new President and CEO of the organization in June 2021 – a trip that simultaneously feels like yesterday and a lifetime ago, given the changes in the industry, health policy, and research environment. The work of NPC has never been more relevant — or more important. We have a great team, and this team appreciates the challenges we face. Here are three reflections I’d offer for anyone interested in the future of innovation. • To meet the challenges of today and tomorrow, NPC has built new capabilities that allow us to build on our 70-year legacy as we conduct rigorous, policy-relevant research and communicate it with impact. I invite you to learn more about the value we provide to NPC members and the benefits member companies experience. https://lnkd.in/etCWVqTE • NPC’s research informs many of the important policy conversations going on right now. To stay up to date on our latest, I hope you subscribe to the NPC This Week Newsletter to get a weekly look-ahead at the policy, research, and industry conversations that matter to the future of biopharmaceutical innovation. https://lnkd.in/eBAj7B_B • I’m proud of the team at NPC and what we’ve accomplished — while recognizing the challenges in front of us. If you’d like to see more of our recent research, analysis, and work, check out our 2023 Annual Report. https://lnkd.in/eB6u2nWd I’ve loved every minute of the past three years and look forward to many more. These aren’t challenges we can solve alone, and it has never been more important for drugmakers, payers, and policymakers to understand the ecosystem and work together for the benefit of patients. If we haven’t spoken in a while, I’d love to hear from you, whether in the DMs, email, or phone. #pharma #innovation #healthpolicy
To view or add a comment, sign in
-
I have pivoted, again. In a work sense, at least. I’m now 8 months in role as a Client Success Manager for Carbon Global We help businesses grow with our human-first approach to lead generation. It is a good fit for me as it builds on the experience I have developed producing TV programmes, setting up and running my own Personal Training business, and managing big brand accounts in the customised led neon lights field. This role makes me happy because it challenges me, and because human-first is part of my fabric. Crucially, Carbon Global is led by good people, who look to improve our service and innovate at every turn. Sharing a recent example of this here. #leadgeneration #clientsuccess #pharma
Welcome to Carbon Connects. A series of videos dedicated to understanding what brand leaders are trying to achieve. Presenting our first season: Pharma Edition featuring Marco Andre 🤖 at Novartis Alyssa Fenoglio at Teva Pharmaceuticals Carolina Quezada Correa at Grünenthal Group Nick Lagan at Grünenthal Group Dr. Goran Martinovic at Boehringer Ingelheim Morgwn Shaw at Bristol Myers Squibb Patrick Markt-Niederreiter at Daiichi Sankyo Europe GmbH Henriette Lonkvist at Ferring Pharmaceuticals Laetitia Bouerat Duvold at Lundbeck Presented by Henry Regan from Carbon Global Make sure you subscribe to our YouTube channel https://lnkd.in/eMbMy8z5 to be notified when the series starts in a few weeks.
To view or add a comment, sign in
-
CEO with a passion for doing good by doing great for the world. “Without planetary health, there is no wealth”!
Great report from Deloitte giving an overview of a decade on IIR and how pharma could get more out of their R&D. At Technobis Group (Technobis Crystallization Systems) we have as our mission “help research succeeds in bringing medicines faster to patients” and with our new #ReactALL technology, developed with a team of scientists from Pfizer we show an increasing R&D effectiveness and quality of experimentation by 40% and minimizing the expensive API. Interested? https://lnkd.in/e8N54JRM
Join me for this Deloitte Academy event where we will be sharing insights from our latest ‘Measuring the return from #pharmaceutical innovation’ report with our expert panel including Paula Gildert, formerly from Takeda and Matt Hefner, Pfizer. We will also discuss how pharma leaders can improve their R&D productivity for clinical trials, utilise #AI and technological innovations and reduce costs alongside M&A. Register to attend online using the link below or contact me directly if you’d like to attend in person in our London offices with our team. https://bit.ly/3VZNc0f #DeloitteUKLSHC #DeloitteRDROI23 Paula Gildert Matthew Hefner Kevin Dondarski Naveed Panjwani Karen Taylor Emily May Andrew Bolt Julian Remnant
To view or add a comment, sign in
4,301 followers